Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates

a technology of pyrrol-3-one and tetrahydrofuro[3,2-b], which is applied in the field of tetrahydrofuro3, 2b pyrrol-3one intermediates, can solve problems such as substantial potency loss

Inactive Publication Date: 2011-10-18
GRUNENTHAL GMBH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patented compound can be made easy-to-access with only one optical rotation (the S configuration) and has very high purity. This makes it ideal for creating various types of drugs that target specific proteins involved in certain diseases such as cancer or inflammatory processes.

Problems solved by technology

The technical problem addressed in this patent text relating to the discovery of novel chemical structures called tissue factors involved in regulating cellular metabolism is the lack of efficient methods for producing certain classes of small molecules containing beta-blocks that can effectively target specific enzymes involved in carbolefin metabolism.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates

Examples

Experimental program
Comparison scheme
Effect test

examples

General Procedures

[0418]Solvents were purchased from ROMIL Ltd, U.K. at SpS or Hi-Dry grade unless otherwise stated. 1H NMR and 13C NMR were obtained on a Bruker DPX400 (400 MHz 1H frequency and 100 MHz 13C frequency; QXI probe) or Bruker Avance 500 MHz (TXI probe with ATM) in the solvents indicated. Chemical shifts are expressed in parts per million (δ) and are referenced to residual signals of the solvent. Coupling constants (J) are expressed in Hz. All analytical HPLC were obtained on Phenomenex Jupiter C4, 5μ, 300 Å, 250×4.6 mm, using mixtures of solvent A (0.1% aq trifluoroacetic acid (TFA)) and solvent B (90% acetonitrile / 10% solvent A) on automated Agilent systems with 215 and / or 254 nm UV detection. Unless otherwise stated a gradient of 10 to 90% B in A over 25 min at 1.5 mL / min was performed for full analytical HPLC. HPLC-MS analysis was performed on an Agilent 1100 series LC / MSD, using automated Agilent HPLC systems, with a gradient of 10 to 90% B in A over 10 min on

example a

Assays for Cysteine Protease Activity

[0635]The compounds of this invention may be tested in one of a number of literature based biochemical assays that are designed to elucidate the characteristics of compound inhibition. The data from these types of assays enables compound potency and the rates of reaction to be measured and quantified. This information, either alone or in combination with other information, would allow the amount of compound required to produce a given pharmacological effect to be determined.

In vitro Cathepsin KiInhibition Measurements

[0636]Stock solutions of substrate or inhibitor were made up to 10 mM in 100% dimethylsulfoxide (DMSO) (Rathburns, Glasgow, U.K.) and diluted as appropriately required. In all cases the DMSO concentration in the assays was maintained at less than 1% (vol. / vol.). The equilibrium inhibition constants (Kiss) for each compound were measured under steady-state conditions monitoring enzyme activity as a function of inhibitor concentration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner GRUNENTHAL GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products